First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

BACKGROUND: Few studies have compared the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), afatinib, with that of reversible EGFR‐TKIs. Therefore, this study assessed the effectiveness of afatinib, erlotinib, and gefitinib in terms of OS (overall su...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Po‐Lan, Chen, Chian‐Wei, Wu, Yi‐Lin, Lin, Chien‐Chung, Su, Wu‐Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862787/
https://www.ncbi.nlm.nih.gov/pubmed/33336895
http://dx.doi.org/10.1111/1759-7714.13462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862787/
https://www.ncbi.nlm.nih.gov/pubmed/33336895
http://dx.doi.org/10.1111/1759-7714.13462

Ejemplares similares